Patients and physicians often disagree on the patient’s disease severity, creating a relationship barrier and frustration among both parties.
By identifying modifiable factors that contribute to differing opinions between patients and physicians regarding the patient’s disease severity, a phenomenon known as discordant severity grading (DSG), researchers found that positive discordance was associated with higher symptom expression and greater quality of life (QOL) impairment among individuals who have psoriasis and eczema.
This cross-sectional study is published in JAMA Dermatology.
“Measures of behavioral, cognitive, and psychological factors are not routinely collected and are thus less readily available,” wrote the study researchers. “However, many of these factors are modifiable and provide a framework for subsequent intervention.”
In the study, the researchers aimed to gain a better understanding of the factors that contribute to differing perceptions on disease severity between patients and physicians and provide direction for the implementation of cognitive behavior interventions that could bridge this discordance. They tested and validated a model with the objective of explaining the cognitive, behavioral, and disease factors associated with DSG. The qualitative theoretical model was validated using structural equation modeling (SEM).
Patients (n = 1057) and their attending physicians (n = 44) were recruited from 3 outpatient dermatological centers in Singapore between October 2021 and September 2022. These patients were aged 18 to 99 years and had been living with psoriasis or eczema for at least 3 months. The data for these patients were analyzed from October 2022 to May 2023.
The primary outcome of the study was a difference in global disease severity scores, which are measured on a scale from 0 to 10—with higher scores indicating greater severity—between the patient and the dermatologist. Positive discordance was defined as a patient-graded severity of 2 points higher than that of the physician, and negative discordance was if a patient's ratng was 2 points lower than the physician.
Of the total patients enrolled, 4 withdrew from the study, leaving 1053 patient-physician pairs available for analysis, in which the mean (SD) age of patients was 43.5 (17.5) years. Additionally, 579 (55%) were male, 802 (76.2%) had eczema, and 251 (23.8%) had psoriasis.
Of the physicians enrolled, 20 (45.5%) were male, 24 (54.5%) were aged 31 to 40 years, 20 (45.5%) were senior residents or fellows, and 14 (31.8%) were consultants or attending physicians. Additionally, the median (IQR) number of patients recruited was 5 (2-18) patients per physician.
A positive discordance was associated with higher symptom expression (standardized coefficient B = 0.12; P = .02) and greater QOL impairment (B = 0.31; P < .001), but not patient or physician demographics.
Furthermore, higher QOL was associated with lower resilience and stability (B = -0.23; P = .02), increased negative social comparisons (B = 0.45; P < .001), lower self-efficacy (B = -0.11; P = .02), increased disease cyclicity (B = 0.47; P < .001), and greater expectation of chronicity (B = 0.18; P < .001).
The researchers acknowledged some limitations to the study, including potential sampling bias and having no existing scale for measuring or defining DGS. Despite these limitations, the researchers believe the study highlights the importance of recognizing and understanding the multivariable factors that contribute to discordance in perceptions of disease severity among physicians and patients with psoriasis and eczema.
“This study brings to the surface key lessons for dermatologists—that many reasons for discordance are, in fact, modifiable,” wrote the researchers. "This paves the way for further interventional work in this area and should be points of focus for the practicing physician.”
Reference
Long V, Chen Z, Du R, et al. Understanding discordant perceptions of disease severity between physicians and patients with eczema and psoriasis using structural equation modeling. JAMA Dermatology. 2023;159(8):811-819. doi:10.1001/jamadermatol.2023.2008
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More